Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Ischemia 1Hemorrhage 1Blood Loss, Surgical 1

Interventions

Paclitaxel 491Carboplatin 436Gemcitabine 394Docetaxel 386Cisplatin 361pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 222Dexamethasone 213Fluorouracil 212Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 161Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 140Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × maleimide-polyethylene glycol-modified hemoglobin, MP4 × Clear all
NCT00425334 2013-08-19

Safety Study of HemospanĀ® in Prostatectomy Patients

Sangart

Phase 2 Completed
20 enrolled
Genitourinary

Hemorrhage, Ischemia, Prostatic Neoplasms, Blood Loss, Surgical

Data powered by HemOnc (CC BY 4.0) Colophon ⚔